DETERMINATION OF SURVIVIN AND PROTEIN KINASE AKT IN PAPILLARY THYROID CARCINOMA AND METASTASIS TISSUES
DOI:
https://doi.org/10.21856/j-PEP.2026.1.01Keywords:
papillary thyroid carcinoma, metastasis, survivin, protein kinase AktAbstract
Background. Survivin is a member of Inhibitors of Apoptosis proteins (IAP) family. It is expressed in actively proliferating cells, and is upregulated in most cancers; consequently, it has received significant attention as a potential oncotherapeutic target. Akt is a central signalling molecule of the phosphoinositide 3-kinase (PI3K)/Akt signalling pathway. It is a serine/threonine-specific protein kinase and involved in apoptosis, proliferation, transcription and migration. Aberrant activation of this pathway has been identified in a wide range of cancers and thyroid as well.
The aim of the study was to compare the expression of survivin and activation of protein kinase Akt in the tissues of patients with goiter, multinodular goiter (MNG), papillary thyroid carcinoma (PTC) with and without metastasis (Mts) to the lymph nodes.
Materials and methods. Postoperative specimens of tumor tissue, metastasis (Mts), benign neoplasms (goiters) and conditionally normal tissue were used for the studies. The expression of survivin mRNA was determined using real-time polymerase chain reaction (qPCR). The expression of Akt was determined using Western-blotting.
Results. The obtained data indicate that the expression of the survivin mRNA in PTC tissue and Mts significantly exceeds the level of its expression in conditionally normal (more than 4.5 times) and goiter tissues. The expression of survivin in PTC without metastasis more than three times lower compared to PTC with metastasis. In metastasis the level of IAP mRNA expression is lower than in the primary tumor. The expression of the phosphorylated (activated) form of Akt in PTC tissue and Mts significantly higher than level of its expression in conditionally normal tissue. The level of Akt in Mts is almost 4 times higher than in the primary tumor and almost 8 times higher than in the conditionally normal tissue.
Сonclusions. Thus, an increased survivin mRNA expression in papillary thyroid carcinoma may be marker of metastasis formation. It can also be used to differentiate between benign and malignant thyroid lesions. The level of the phosphorylated (activated) form of Akt is especially high in metastasis.
References
1. Wheatley SP, Altieri DC. J Cell Sci 2019;132(7): jcs223826. https://doi.org/10.1242/jcs.223826.
2. Siragusa G, Tomasello L, Giordano C, Pizzolanti G. Life Sci 2024;350: 122788. https://doi.org/10.1016/j.lfs.2024.122788.
3. Adamopoulos PG, Tsiakanikas P, Adam EE, Scorilas A. Genomics 2021;113(1 Pt 2): 573-581. https://doi.org/10.1016/j.ygeno.2020.09.053.
4. Nan XW, Gong LH, Chen X, et al. Front Oncol 2019;9: 1345. https://doi.org/10.3389/fonc.2019.01345.
5. Pannone G, Santoro A, Pasquali D, et al. Thyroid 2014;24(3): 511-519. https://doi.org/10.1089/thy.2013.0196.
6. Zhang S, Zhang C, Song Y, et al. Medicine (Baltimore) 2018;97(17): e0571. https://doi.org/10.1097/MD.0000000000010571.
7. Yusufu A, Tuerdi R, Redati D, et al. Oncol Lett 2020;20(6): 297. https://doi.org/10.3892/ol.2020.12160.
8. Zheng HC. Oncotarget 2017;8(35): 59950-59964. https://doi.org/10.18632/oncotarget.19048.
9. Islam M, Jones S, Ellis I. Biomedicines 2023;11(11): 3001. https://doi.org/10.3390/biomedicines11113001.
10. Chomczynski P, Sacchi N. Anal Biochem 1987;162(1): 156-159. https://doi.org/10.1006/abio.1987.9999.
11. Pushkarev VM, Kovzun OI, Voskoboynyk LG. Endokrynologia 2008;13(1): 58-65.
12. Sule R, Rivera G, Gomes AV. Biotechniques 2023;75(3): 99-114. https://doi.org/10.2144/btn-2022-0034.
13. Jaiswal PK, Goel A, Mittal RD. Indian J Med Res 2015;141(4): 389-397. https://doi.org/10.4103/0971-5916.159250.
14. Niciporuka R, Nazarovs J, Ozolins A, et al. Medicina (Kaunas) 2021;57(10): 1131. https://doi.org/10.3390/medicina57101131.
15. Cho HJ, Kim HR, Park YS, et al. Surg Oncol 2015;24(4): 329-334. https://doi.org/10.1016/j.suronc.2015.09.001.
16. Selemetjev SA, Savin SB, Paunovic IR, et al. Wien Klin Wochenschr 2015;127(9-10): 337-344. https://doi.org/10.1007/s00508-014-0674-6.
17. Li JY, Shi J, Sang JF, et al. Genet Mol Res 2015;14(4): 15102-15111, available at: https://www.geneticsmr.org/articles/role-of-survivin-in-the-pathogenesis-of-papillary-thyroid-carcinoma.pdf.
18. Selemetjev S, Dencic TI, Marecko I, et al. Pathol Res Pract 2014;210(1): 30-34. https://doi.org/10.1016/j.prp.2013.09.014.
19. Selemetjev S, Savin S, Paunovic I, et al. J Cancer Res Ther 2018;14: S114-S119. https://doi.org/10.4103/0973-1482.163675.
20. Zinich PP, Pushkarev VM, Bolgov MYu, et al. Endokrynologia 2020;25(3): 249-264. https://doi.org/10.31793/1680-1466.2020.25-3.227.
21. Kobrynska NYa, Pushkarev VM, Levchuk NI, et al. Endokrynologia 2024;29(4): 372-379. https://doi.org/10.31793/1680-1466.2024.29-4.372.
22. Waligórska-Stachura J, Sawicka-Gutaj N, Zabel M, et al. Oncol Lett 2017;13(4): 2437-2441. https://doi.org/10.3892/ol.2017.5713.
23. Mahmoudian-Sani MR, Alghasi A, Saeedi-Boroujeni A, et al. Pathol Res Pract 2019;215(4): 619-625. https://doi.org/10.1016/j.prp.2019.01.025.
24. Gu Y, Jin S, Wang F, et al. Biomed Pharmacother 2014;68(4): 471-475. https://doi.org/10.1016/j.biopha.2014.03.010.
25. Simonetti O, Lucarini G, Rubini C, et al. Anticancer Res 2015;35(4): 2113-2120.
26. Martínez-García D, Manero-Rupérez N, Quesada R, et al. Med Res Rev 2019;39(3): 887-909. https://doi.org/10.1002/med.21547.
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Kobrynska N. Ya., Pushkarev V. M., Levchuk N. I., Kovzun O. I., Komisarenko I. I., Guda B. B., Tronko M. D.
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 
ISSN 
